Tuesday's Health Winners & Losers
Earnings, a Food and Drug Administration warning and clinical updates blotted the biotech sector Tuesday, but health indices lay flat.
Analysts surveyed by Thomson financial were looking for 72 cents a share on revenue of $2.93 billion. Genentech reported revenue of $2.91 billion before items (and including $3 million associated with the acquisition of Tanox), a 22% increase over operating revenue of $2.38 billion in the third quarter of 2006. Shares were down $2.39, or 3.1%, at $ 75.11 on Tuesday.
Forest Laboratories (FRX) on Tuesday reported earnings that were affected by a $70 million licensing charge (equating to 15 cents a share net of tax) to Microbia for the right to co-develop and co-market constipation treatment linaclotide. The company reported earning 71 cents a share for the second quarter of fiscal 2008. Analysts surveyed by Thomson Financial had expected 74 cents a share.Forest Labs shares fell 4.8% to $38.46. The stock is a component of the Amex Pharmaceutical index, which was down 3.70, or 1.1%, to 347.85. Up on earnings, biotechnology company Enzo Biochem (ENZ) reported that its fiscal fourth-quarter (ended July 31) loss narrowed due to a rise in sales at its clinical lab segment and new product revenue from its acquisition of Axxora Life Sciences. The company reported a loss of $3.3 million, or 9 cents a share, compared to a loss of $4.5 million, or 14 cents a share, in the year-ago quarter. Analysts surveyed by Thomson Financial expected a loss of 12 cents a share on revenue of $16.3 million. Enzo said its revenue rose 81% to $17.9 million from $9.9 million in 2006. Shares climbed 13.4% to $13.14.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV